{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:33:25Z","timestamp":1788431605070,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Otsuka Pharmaceutical Europe Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1290-5","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T13:03:10Z","timestamp":1556024590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model"],"prefix":"10.1186","volume":"20","author":[{"given":"Hayley","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"issue":"9981","key":"1290_CR1","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong AC, Devuyst O, Knebelmann B, Walz G, ERA-EDTA Working Group for Inherited Kidney Diseases. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385(9981):1993\u20132002.","journal-title":"Lancet."},{"issue":"suppl 4","key":"1290_CR2","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA registry. Nephrol Dial Transplant. 2014;29(suppl 4):iv15\u201325.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1290_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant. 2016;31(3):337\u201348.","journal-title":"Nephrol Dial Transplant"},{"key":"1290_CR4","unstructured":"Pharmaceuticals and medical devices agency. Review report: Samsca 2014 [28 Feburary 2018]. Available from: \n                    http:\/\/www.pmda.go.jp\/files\/000208511.pdf"},{"key":"1290_CR5","unstructured":"European Medicines Agency. European public assessment report - product information: Jinarc (tolvaptan) 2017 [16 January 2018]. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002788\/WC500187921.pdf\n                    \n                  ."},{"key":"1290_CR6","unstructured":"Therapeutic Goods Administration. Australian public assessment report for tolvaptan 2018 [1 March 2018]. Available from: \n                    https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-tolvaptan-180209.pdf\n                    \n                  ."},{"key":"1290_CR7","unstructured":"Otsuka Pharmaceutical Co. Ltd. Otsuka's JYNARQUE\u2122 (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD) 2018 [9 May 2018]. Available from: \n                    https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2018\/20180425_1.html\n                    \n                  ."},{"issue":"25","key":"1290_CR8","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med"},{"issue":"2","key":"1290_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1053\/j.ajkd.2016.08.028","volume":"69","author":"NF Casteleijn","year":"2017","unstructured":"Casteleijn NF, Blais JD, Chapman AB, Czerwiec FS, Devuyst O, Higashihara E, et al. Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial. Am J Kidney Dis. 2017;69(2):210\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1290_CR10","doi-asserted-by":"publisher","first-page":"CJN.06300615","DOI":"10.2215\/CJN.06300615","volume":"11","author":"VE Torres","year":"2016","unstructured":"Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3: 4 trial. Clin J Am Soc Nephrol. 2016;11:CJN.06300615.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1290_CR11","doi-asserted-by":"crossref","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4: 4 trial. Nephrology Dialysis Transplantation. 2017:1\u201313.","DOI":"10.1093\/ndt\/gfx079"},{"issue":"20","key":"1290_CR12","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930\u201342.","journal-title":"N Engl J Med"},{"key":"1290_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12882-017-0804-2","volume":"19","author":"P McEwan","year":"2018","unstructured":"McEwan P, Bennett Wilton H, Ong A, \u00d8rskov B, Sandford R, Scolari F, et al. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD outcomes model. BMC Nephrol. 2018;19:37.","journal-title":"BMC Nephrol"},{"issue":"9","key":"1290_CR14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"1290_CR15","unstructured":"Otsuka Pharmaceutical Development & Commercialization Inc. Clinical study report. Protcol no. 156-13-210. A phase 3b, multi-center, randomized-withdrawal, placebo-controlled, double-blind, parallel-group trial to compare the efficacy and safety of Tolvaptan (45 to 120 mg\/day, Split-dose) in subjects with chronic kidney disease between late stage 2 to early stage 4 due to autosomal dominant polycystic kidney disease. 2017."},{"issue":"1","key":"1290_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"1290_CR17","unstructured":"National Institute for Health and Care Excellence. Tolvaptan for treating autosomal dominant polycystic kidney disease. Technology appraisal guidance [TA358] 2015 [30 November 2016]. Available from: \n                    https:\/\/www.nice.org.uk\/guidance\/ta358"},{"key":"1290_CR18","unstructured":"Scottish Medicines Consortium. tolvaptan (Jinarc) 2016 [28 April 2017]. Available from: \n                    https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/tolvaptan-jinarc-fullsubmission-111415\/"},{"issue":"6","key":"1290_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.7326\/0003-4819-159-6-201309170-00004","volume":"159","author":"KF Erickson","year":"2013","unstructured":"Erickson KF, Chertow GM, Goldhaber-Fiebert JD. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med. 2013;159(6):382\u20139.","journal-title":"Ann Intern Med"},{"issue":"2\u20133","key":"1290_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10754-007-9025-8","volume":"7","author":"I Durand-Zaleski","year":"2007","unstructured":"Durand-Zaleski I, Combe C, Lang P. International study of health care organization and financing for end-stage renal disease in France. Int J Health Care Finance Econ. 2007;7(2\u20133):171\u201383.","journal-title":"Int J Health Care Finance Econ"},{"issue":"2\u20133","key":"1290_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10754-007-9016-9","volume":"7","author":"G Pontoriero","year":"2007","unstructured":"Pontoriero G, Pozzoni P, Del Vecchio L, Locatelli F. International study of health care organization and financing for renal replacement therapy in Italy: an evolving reality. Int J Health Care Finance Econ. 2007;7(2\u20133):201\u201315.","journal-title":"Int J Health Care Finance Econ"},{"issue":"2\u20133","key":"1290_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000350142","volume":"37","author":"CC Adarkwah","year":"2013","unstructured":"Adarkwah CC, Gandjour A, Akkerman M, Evers S. To treat or not to treat? Cost-effectiveness of ace inhibitors in non-diabetic advanced renal disease-a Dutch perspective. Kidney Blood Press Res. 2013;37(2\u20133):168\u201380.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"1290_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/HJH.0000000000000071","volume":"32","author":"O Borisenko","year":"2014","unstructured":"Borisenko O, Beige J, Lovett EG, Hoppe UC, Bjessmo S. Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings. J Hypertens. 2014;32(3):681\u201392.","journal-title":"J Hypertens"},{"issue":"3","key":"1290_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00134-012-2760-4","volume":"39","author":"A Laukkanen","year":"2013","unstructured":"Laukkanen A, Emaus L, Pettil\u00e4 V, Kaukonen K-M. Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective. Intensive Care Med. 2013;39(3):406\u201313.","journal-title":"Intensive Care Med"},{"issue":"9","key":"1290_CR25","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1007\/s00134-005-2681-6","volume":"31","author":"A \u00c5hlstr\u00f6m","year":"2005","unstructured":"\u00c5hlstr\u00f6m A, Tallgren M, Peltonen S, R\u00e4s\u00e4nen P, Pettil\u00e4 V. Survival and quality of life of patients requiring acute renal replacement therapy. Intensive Care Med. 2005;31(9):1222\u20138.","journal-title":"Intensive Care Med"},{"key":"1290_CR26","doi-asserted-by":"crossref","unstructured":"Eriksson D, Karlsson L, Eklund O, Dieperink H, Honkanen E, Melin J, et al. Health-related quality of life across all stages of autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation. 2016:gfw335.","DOI":"10.1093\/ndt\/gfw335"},{"key":"1290_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1186\/s12913-017-2513-8","volume":"17","author":"D Eriksson","year":"2017","unstructured":"Eriksson D, Honkanen E, Dieperink H, Melin J, Lundberg J, Selvig K, et al. Real-world costs of autosomal dominant polycystic kidney disease in the Nordics. BMC Health Serv Res. 2017;17:560.","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"1290_CR28","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.2215\/CJN.04610709","volume":"4","author":"SV Jassal","year":"2009","unstructured":"Jassal SV, Watson D. Dialysis in late life: benefit or burden. Clin J Am Soc Nephrol. 2009;4(12):2008\u201312.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1290_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12882-015-0114-5","volume":"16","author":"C Woon","year":"2015","unstructured":"Woon C, Bielinski-Bradbury A, O\u2019Reilly K, Robinson P. A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2015;16(1):140.","journal-title":"BMC Nephrol"},{"issue":"5","key":"1290_CR30","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1053\/j.ajkd.2017.10.023","volume":"71","author":"GM Brosnahan","year":"2018","unstructured":"Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, et al. Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a post hoc analysis from the HALT-PKD trials. Am J Kidney Dis. 2018;71(5):666\u201376.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1290_CR31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2018.01.052","volume":"71","author":"M Neagu","year":"2018","unstructured":"Neagu M, Coca D, Ong AC. Linear and nonlinear estimated GFR slopes in ADPKD patients reaching ESRD. Am J Kidney Dis. 2018;71(6):912\u20133.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1290_CR32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/ki.1992.195","volume":"41","author":"PA Gabow","year":"1992","unstructured":"Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992;41(5):1311\u20139.","journal-title":"Kidney Int"},{"key":"1290_CR33","doi-asserted-by":"crossref","unstructured":"Brosnahan G, Abebe K, Moore C, Bae K, Braun W, Chapman A, et al. Determinants of progression in early autosomal dominant polycystic kidney disease-is it blood pressure or renin-angiotensin-aldosterone-system blockade? Curr Hypertens Rev. 2018.","DOI":"10.2174\/1573402114666180322110209"},{"key":"1290_CR34","unstructured":"Otsuka Pharmaceutical Development & Commercialization Inc. Amended Clinical Study Report. Protcol No. 156\u201304-251. A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease. 2013."},{"issue":"4","key":"1290_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","volume":"1","author":"MV Irazabal","year":"2016","unstructured":"Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Chapman AB, Devuyst O, et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3: 4 clinical trial. Kidney Int Rep. 2016;1(4):213\u201320.","journal-title":"Kidney Int Rep"},{"key":"1290_CR36","unstructured":"Otsuka Pharmaceutical Development & Commercialization Inc. Clinical Study Report. Protcol No. 156\u201308-271. Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD). 2016."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1290-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1290-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1290-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T23:14:00Z","timestamp":1587510840000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1290-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1290"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1290-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]},"assertion":[{"value":"23 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is based on previously conducted research and does not involve any new studies of human or animal subjects performed by any of the authors, as such ethics approval and consent to participate were not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HBW, PM and KH have served as consultants to and received research funding from Otsuka Pharmaceutical Europe Ltd. in relation to this study. KO is an employee of Otsuka Pharmaceutical Europe Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"136"}}